AbbVie ABBV
NYSE ABBV
$276.48 +4.06 (+1.49%)
At close: Oct 9, 2026 · 4:00 PM EDT

AbbVie (ABBV) Net Income towards Common Stockholders (2012 - 2026)

Updated

AbbVie (ABBV) posted Net Income towards Common Stockholders of $3.61 billion for Q2 2026, up 285.2% from $938 million a year earlier and up 419.9% from the prior quarter.

Analysis

AbbVie (ABBV) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Net Income towards Common Stockholders at AbbVie was $6.31 billion, up 67.7% year-over-year; for FY2025, it came in at $4.23 billion, down 1.2% from FY2024.

  • Annual Net Income towards Common Stockholders has declined for three consecutive years, with a five-year compound annual growth rate of -1.7% (FY2020 to FY2025).
  • In prior years, AbbVie's Net Income towards Common Stockholders was $4.28 billion in FY2024 (-12.0%), $4.86 billion in FY2023 (-58.9%), $11.84 billion in FY2022 (+2.5%) and $11.54 billion in FY2021 (+150.0%).
  • The Q2 2026 figure stands as the highest quarterly Net Income towards Common Stockholders since Q3 2022.
  • On a year-over-year basis, Net Income towards Common Stockholders increased in 1 of the last six quarters, with growth averaging 16.9%.
  • The strongest year-over-year quarter for Net Income towards Common Stockholders in the past five years was Q1 2024, with growth of 472.8%; the weakest was Q1 2023, with a decline of 94.7%.
  • According to Business Quant data, Net Income towards Common Stockholders for the three prior quarters was $695 million (Q1 2026), $1.82 billion (Q4 2025) and $186 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,109.58 Bn 1,078.16 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 630.16 Bn 548.69 Bn 17.26 Bn 5.53 Bn
3 AbbVie 488.57 Bn 461.73 Bn 12.70 Bn 3.61 Bn
4 Merck 359.15 Bn 313.58 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 274.32 Bn 238.71 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 246.73 Bn 220.50 Bn 12.86 Bn 2.51 Bn
7 Amgen 224.28 Bn 179.68 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 187.60 Bn 161.71 Bn 6.22 Bn -10.50 Bn
9 Pfizer 161.13 Bn 108.08 Bn 10.94 Bn -248.00 Mn
10 Vertex Pharmaceuticals 129.23 Bn 101.23 Bn 2.84 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.61 Bn
Mar 31, 2026 695.00 Mn
Dec 31, 2025 1.82 Bn
Sep 30, 2025 186.00 Mn
Jun 30, 2025 938.00 Mn
Mar 31, 2025 1.29 Bn
Dec 31, 2024 -22.00 Mn
Sep 30, 2024 1.56 Bn
Jun 30, 2024 1.37 Bn
Mar 31, 2024 1.37 Bn
Dec 31, 2023 822.00 Mn
Sep 30, 2023 1.78 Bn
Jun 30, 2023 2.02 Bn
Mar 31, 2023 239.00 Mn
Dec 31, 2022 2.47 Bn
Sep 30, 2022 3.95 Bn
Jun 30, 2022 924.00 Mn
Mar 31, 2022 4.49 Bn
Dec 31, 2021 4.04 Bn
Sep 30, 2021 3.18 Bn
API Access

AbbVie Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ABBV&period=max&api_key=YOUR_API_KEY